This course is currently available for physicians only.
Breast cancer debate of the year 2024
During
the 2024 edition of the breast cancer debate of the year, an esteemed panel of
breast cancer experts addressed several unanswered questions in the care for
patients with early-stage breast cancer (EBC). In three pro-con sessions, the
experts respectively discussed the current indication for anthracyclines in
chemotherapy regimens for patients with EBC, tackled the need for an axillary
lymph node dissection (ALND) in the contemporary management of EBC patients and
discussed the feasibility of de-escalating chemotherapy in patients with stage
I triple negative breast cancer (TNBC). In addition to these interesting
debates, the breast cancer debate of the year featured a critical review of the
clinical trial data supporting the use of CDK4/6 inhibitors in the adjuvant
treatment of patients with hormone-receptor positive, HER2-negative EBC.
Breast cancer debate of the year 2024
Expert panel:
Dr Pierre Fodart
Dr Caroline Duhem
Dr Donatienne Taylor
Dr Maxima Van Houdt
Dr Ann Smeets
Dr Alex De Caluwé
Dr Elisa Agostinetto
Prof Michail Ignatiadis
Prof Jerusalem
Prof Ahmad Awada
Dr Caroline Duhem
Dr Donatienne Taylor
Dr Maxima Van Houdt
Dr Ann Smeets
Dr Alex De Caluwé
Dr Elisa Agostinetto
Prof Michail Ignatiadis
Prof Jerusalem
Prof Ahmad Awada